{"pmid":32333823,"title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","text":["Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches.","J Eur Acad Dermatol Venereol","Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T","32333823"],"abstract":["Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches."],"journal":"J Eur Acad Dermatol Venereol","authors":["Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333823","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16525","keywords":["covid-19","sars-cov-2","pemphigoid","pemphigus"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1665071049790717952,"score":8.518259,"similar":[{"pmid":32170800,"title":"Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.","text":["Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.","Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear, and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection.","Dermatol Ther","Yan, Yicen","Chen, Hui","Chen, Liuqing","Cheng, Bo","Diao, Ping","Dong, Liyun","Gao, Xinghua","Gu, Heng","He, Li","Ji, Chao","Jin, Hongzhong","Lai, Wei","Lei, Tiechi","Li, Li","Li, Liuyi","Li, Ruoyu","Liu, Dongxian","Liu, Wei","Lu, Qianjin","Shi, Ying","Song, Jiquan","Tao, Juan","Wang, Baoxi","Wang, Gang","Wu, Yan","Xiang, Leihong","Xie, Jun","Xu, Jinhua","Yao, Zhirong","Zhang, Furen","Zhang, Jianzhong","Zhong, Shaomin","Li, Hengjin","Li, Hang","32170800"],"abstract":["Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear, and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection."],"journal":"Dermatol Ther","authors":["Yan, Yicen","Chen, Hui","Chen, Liuqing","Cheng, Bo","Diao, Ping","Dong, Liyun","Gao, Xinghua","Gu, Heng","He, Li","Ji, Chao","Jin, Hongzhong","Lai, Wei","Lei, Tiechi","Li, Li","Li, Liuyi","Li, Ruoyu","Liu, Dongxian","Liu, Wei","Lu, Qianjin","Shi, Ying","Song, Jiquan","Tao, Juan","Wang, Baoxi","Wang, Gang","Wu, Yan","Xiang, Leihong","Xie, Jun","Xu, Jinhua","Yao, Zhirong","Zhang, Furen","Zhang, Jianzhong","Zhong, Shaomin","Li, Hengjin","Li, Hang"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32170800","week":"202011|Mar 09 - Mar 15","doi":"10.1111/dth.13310","keywords":["covid-19","sars-cov-2","healthcare workers","protect","skin and mucous membrane barrier"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874708992000,"score":159.9599},{"pmid":32205186,"pmcid":"PMC7102591","title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","text":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!","The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.","Autoimmun Rev","Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto","32205186"],"abstract":["The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients."],"journal":"Autoimmun Rev","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205186","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.autrev.2020.102523","keywords":["COVID-19","Coronavirus","Cytokine release syndrome","DMARDs","Rheumatoid arthritis","Treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352133689278465,"score":150.96921},{"pmid":32315487,"title":"Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.","text":["Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.","We aimed to report the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by SARS-CoV-2. The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory-confirmed severe and critical cases of COVID-19 from the intensive care unit (ICU) ward of the Huangshi Central Hospital, Hubei Province, China were investigated. A total of 21 patients (13 males and eight females) including eight (38.1%) severe cases and 13 (61.9%) critical cases were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most of them (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest CT were ground-glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurements were lymphocytopenia (85.7%), elevated levels of C-reactive protein (94.7%), and Interleukin-6 (89.5%). The prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibody in the cases was 20%, 25% and 50% respectively. In the present work, we retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases with COVID-19. Autoimmune phenomena exist in COVID-19 subjects, and the results provide the rationale for a strategy of prevention of dysfunction of immune and optimal immunosuppressive therapy in the future.","Clin Transl Sci","Zhou, Yaqing","Han, Tao","Chen, Jiaxin","Hou, Can","Hua, Lei","He, Shu","Guo, Yi","Zhang, Sheng","Wang, Yanjun","Yuan, Jinxia","Zhao, Chenhui","Zhang, Jing","Jia, Qiaowei","Zuo, Xiangrong","Li, Jinhai","Wang, Liansheng","Cao, Quan","Jia, Enzhi","32315487"],"abstract":["We aimed to report the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by SARS-CoV-2. The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory-confirmed severe and critical cases of COVID-19 from the intensive care unit (ICU) ward of the Huangshi Central Hospital, Hubei Province, China were investigated. A total of 21 patients (13 males and eight females) including eight (38.1%) severe cases and 13 (61.9%) critical cases were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most of them (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest CT were ground-glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurements were lymphocytopenia (85.7%), elevated levels of C-reactive protein (94.7%), and Interleukin-6 (89.5%). The prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibody in the cases was 20%, 25% and 50% respectively. In the present work, we retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases with COVID-19. Autoimmune phenomena exist in COVID-19 subjects, and the results provide the rationale for a strategy of prevention of dysfunction of immune and optimal immunosuppressive therapy in the future."],"journal":"Clin Transl Sci","authors":["Zhou, Yaqing","Han, Tao","Chen, Jiaxin","Hou, Can","Hua, Lei","He, Shu","Guo, Yi","Zhang, Sheng","Wang, Yanjun","Yuan, Jinxia","Zhao, Chenhui","Zhang, Jing","Jia, Qiaowei","Zuo, Xiangrong","Li, Jinhai","Wang, Liansheng","Cao, Quan","Jia, Enzhi"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315487","week":"202017|Apr 20 - Apr 26","doi":"10.1111/cts.12805","keywords":["autoimmune characteristics","clinical characteristics","coronavirus disease-19 (covid-19)","sars-cov-2","severe and critical cases"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664714520048697347,"score":140.70552},{"pmid":32333552,"title":"Recommendations for Deep Brain Stimulation Device Management During a Pandemic.","text":["Recommendations for Deep Brain Stimulation Device Management During a Pandemic.","Most medical centers are postponing elective procedures and deferring non-urgent clinic visits to conserve hospital resources and prevent spread of COVID-19. The pandemic crisis presents some unique challenges for patients currently being treated with deep brain stimulation (DBS). Movement disorder (Parkinson's disease, essential tremor, dystonia), neuropsychiatric disorder (obsessive compulsive disorder, Tourette syndrome, depression), and epilepsy patients can develop varying degrees of symptom worsening from interruption of therapy due to neurostimulator battery reaching end of life, device malfunction or infection. Urgent intervention to maintain or restore stimulation may be required for patients with Parkinson's disease who can develop a rare but potentially life-threatening complication known as DBS-withdrawal syndrome. Similarly, patients with generalized dystonia can develop status dystonicus, patients with obsessive compulsive disorder can become suicidal, and epilepsy patients can experience potentially life-threatening worsening of seizures as a result of therapy cessation. DBS system infection can require urgent, and rarely emergent surgery. Elective interventions including new implantations and initial programming should be postponed. For patients with existing DBS systems, the battery status and electrical integrity interrogation can now be performed using patient programmers, and employed through telemedicine visits or by phone consultations. The decision for replacement of the implantable pulse generator to prevent interruption of DBS therapy should be made on a case-by-case basis taking into consideration battery status and a patient's tolerance to potential therapy disruption. Scheduling of the procedures, however, depends heavily on the hospital system regulations and on triage procedures with respect to safety and resource utilization during the health crisis.","J Parkinsons Dis","Miocinovic, Svjetlana","Ostrem, Jill L","Okun, Michael S","Bullinger, Katie L","Riva-Posse, Patricio","Gross, Robert E","Buetefisch, Cathrin M","32333552"],"abstract":["Most medical centers are postponing elective procedures and deferring non-urgent clinic visits to conserve hospital resources and prevent spread of COVID-19. The pandemic crisis presents some unique challenges for patients currently being treated with deep brain stimulation (DBS). Movement disorder (Parkinson's disease, essential tremor, dystonia), neuropsychiatric disorder (obsessive compulsive disorder, Tourette syndrome, depression), and epilepsy patients can develop varying degrees of symptom worsening from interruption of therapy due to neurostimulator battery reaching end of life, device malfunction or infection. Urgent intervention to maintain or restore stimulation may be required for patients with Parkinson's disease who can develop a rare but potentially life-threatening complication known as DBS-withdrawal syndrome. Similarly, patients with generalized dystonia can develop status dystonicus, patients with obsessive compulsive disorder can become suicidal, and epilepsy patients can experience potentially life-threatening worsening of seizures as a result of therapy cessation. DBS system infection can require urgent, and rarely emergent surgery. Elective interventions including new implantations and initial programming should be postponed. For patients with existing DBS systems, the battery status and electrical integrity interrogation can now be performed using patient programmers, and employed through telemedicine visits or by phone consultations. The decision for replacement of the implantable pulse generator to prevent interruption of DBS therapy should be made on a case-by-case basis taking into consideration battery status and a patient's tolerance to potential therapy disruption. Scheduling of the procedures, however, depends heavily on the hospital system regulations and on triage procedures with respect to safety and resource utilization during the health crisis."],"journal":"J Parkinsons Dis","authors":["Miocinovic, Svjetlana","Ostrem, Jill L","Okun, Michael S","Bullinger, Katie L","Riva-Posse, Patricio","Gross, Robert E","Buetefisch, Cathrin M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333552","week":"202017|Apr 20 - Apr 26","doi":"10.3233/JPD-202072","keywords":["covid-19","dbs withdrawal","battery depletion","coronavirus","telemedicine"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1665071049795960834,"score":139.6951},{"pmid":32277351,"title":"Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.","text":["Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.","Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed.","Am J Clin Dermatol","Torres, Tiago","Puig, Luis","32277351"],"abstract":["Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed."],"journal":"Am J Clin Dermatol","authors":["Torres, Tiago","Puig, Luis"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277351","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s40257-020-00514-2","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636943905849344,"score":121.422424}]}